Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-06-12
2007-06-12
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S205100, C424S207100, C435S236000
Reexamination Certificate
active
11111900
ABSTRACT:
Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.
REFERENCES:
patent: 6080408 (2000-06-01), Rovinski et al.
patent: 6451322 (2002-09-01), Rovinski et al.
patent: 6544527 (2003-04-01), Rovinski et al.
patent: 6923970 (2005-08-01), Rovinski et al.
patent: WO 89/05349 (1989-06-01), None
patent: WO 91/05860 (1991-05-01), None
patent: WO 91/05864 (1991-05-01), None
patent: WO 91/07425 (1991-05-01), None
patent: WO 93/20220 (1993-10-01), None
patent: WO 96/05292 (1996-02-01), None
Rovinski, B. et al; (1992) J. Virol., 66, pp. 4003-4012.
Wain-Hobson, S. et al; (1985) Cell, 40, pp. 9-17.
Myers, G. et al; (ed.) (1990) Human retroiruses and AIDS, Theoretical Biology and Biophysics, Group T-10. Los Alamos National Laboratory, Los Alamos, N. Mex.
Alizon, M., et al; (1984) Nature, 312, pp. 757-780.
Min Jou, W., et al; (1980) Cell, 19, pp. 683-696.
Westhof, E., et al; (1984) Nature, 311, pp. 123-126.
Trifilieff, E., et al; (1991) Mol. Immunol., 28, pp. 889-896.
Kieny, M.P. (1990) J. Acquired Immune Deficiency Syndromes, 3, pp. 395-402.
Ulmer, J.B., et al; (1993) Curr. Opin. Invest. Drugs 2(9), pp. 983-989.
Martin et al; 1993, J. Biol. Chm. 268: pp. 2565-2570.
Berman, et al; 1990, Nature 345: pp. 622-625.
Klein, M. et al; AIDS Research and Human Retroviruses, “Development of a cross-neutralizing HIV-1 pseudovirion-based vaccine” vol. 9. Sup 1, Oct. 1993.
Bowles, et al; Virology, “Site-directed mutagenesis of the P2 region of the Rous Sarcoma Virus gag gene: effects on gag polyproptein processing”, vol. 203, No. 1, Aug. 15, 1994, pp. 20-28. XP002003497.
Sakalian, M. et al; Journal of Virology, “Efficiency and Selectivity of RNA packaging by Rous Sarcoma Virus gag delection mtants”, vol. 68, No. 9, Sep. 1994, pp. 5969-6981 XP000560252.
Zhang, Y. et al; Journal of Virology, Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation, vol. 69, No. 9 pp. 5716-5722. XP002003498.
Coffin, J. 1996, “Retroviridae: The Viruses and Their Replication”, in Fields Viroloy, Third Edition, Fields et al, eds., Lippincott-Raven Publishers, Philadelphia, p. 1770.
Hunter, E. 1994 Sem /vurik. 5: pp. 71-83.
Karacistas et al, 993, Virol. 193: pp. 661-671.
Drelich et al., “Identification of amino acic residues critical for endonuclease and integration activities of HIV-1 IN protein in viro, ”Virology, 1992, 188(2): pp. 459-468.
Haynes, J., et al, 1991, “Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines”, AIDS Res. Human retrovir. 7(1): pp. 17-27.
Aldovini, A. and R. Young, 1990, “Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus”, J. Virol. 64(5): pp. 1920-1926.
Gorelick, R., et al; 1993, “The two zinc fingers in the human immunodeficiency virus type 1 nucleocapsid protein are not functionally equivalent”, Virol. 67(7): pp. 4027-4036.
Tisdale, M., et al; 1991, “Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity”, J. Gen. Virol. 72: pp. 59-66.
Shaharabany, M., et al; “Expression and mutational analysis of the reverse transcriptase of the lentivirus equine infectious anemia virus”, Bioche. Biophys. Res. Comm. 196(2): pp. 914-920.
Edelman, R. and C. Tacket, 1990, “Adjuvants”, Intern. Rev. Immunol. 7: pp. 51-66.
Gorelick, J.R. et al; noninfectious human immunodeficiency virus type 1 mutants deficient in Genomic RNA. (1990) vol. 64, No. 7, pp. 3207-3211.
Dannull, J. et al; Specific binding of HIV-1 nucleocapsid protein to PSI RNA in viro requires N-terminal zinc finger and flanking basic amino acid residues. (1994) vol. 13, No. 7 pp. 1525-1533.
Dupraz P., et al; Point mutations in the proximal Cys-His Box of Rous Sarcoma virus nucleocapsid protein. J. of Virology (1990) Vo. 64, No. 10, pp. 4978-4987.
Wakefield, K. J. et al; In vitro enzymatic activity of Human Immunodeficiency virus type 1 reverse transcriptase mutants in the hihly conserved YMDD Amino Acid Motif correlates with the infectious potencial of the proviral genome. (1992) vol. 66, No. 11, pp. 6806-68122.
Cao Shi-Xian
Klein Michel H.
Persson Roy
Rovinski Benjamin
Yao Fei-Long
Humphrey Louise
Parkin Jeffrey S.
Sanofi Pasteur Limited
Sim & McBurney
Stewart Michael I.
LandOfFree
Retrovirus-like particles made non-infectious by a plurality... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retrovirus-like particles made non-infectious by a plurality..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retrovirus-like particles made non-infectious by a plurality... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3864155